Tirzepatide for the Treatment of Cannabis Use Disorder

Inclusion Criteria: * English speaking adults aged 18 and above * Diagnosed with DSM-5 cannabis use disorder, severe Exclusion Criteria: * Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent * Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating or * Comorbid substance use disorder * BMI\<21 kg/m2 * Current or lifetime diagnosis of Type 1 or Type 2 diabetes * Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 * Use of any glucagon-like peptide -1 agonist medications in the prior 3 months * Anticipating receipt of any glucagon-like peptide-1 agonist medications during the trial * Current hypoglycemia as indicated by a blood sugar level of \<71 mg/dL measured at baseline visit, as well as visits 2 and 4. * Untreated cholelithiasis or gallbladder disease * History of acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days * Systolic blood pressure persistently above 160 mmHg or diastolic blood pressure persistently above 100 mmHg during screening * History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy * Liver function test greater than 3 times upper normal limit * Renal impairment as indicated by estimated glomerular filtration rate (eGFR) of \<30 * History of hypersensitivity or allergy to tirzepatide * Pregnant or breastfeeding * Individuals taking glucagon-like peptide-1 agonists or other weight loss drugs. * Anticipated to participate in a concurrent drug trial * Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant